Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant.

NCT05234190 is registered in ClinicalTrials.gov with Quell Therapeutics Limited as lead sponsor.

NCT NCT05234190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05234190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant.
Lead sponsor
Quell Therapeutics Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 21, 2022
Completion date
September 30, 2040
Enrollment
33 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

liver diseases, liver failure, rejection; transplant, liver